Abstract

Omer Ibrahim A Omer52753* and Abdelhafiz Mohammed Abdalla52754

Background: The aim of this study is to investigate the risk of lung cancer linked with the use of Angiotensin- Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARB) and Overall Survival for lung cancer.

Methods: By using specific terminologies related to cancer and the inhibitors of ACEIs/ARBs, we searched on several research databases for studies that used to investigate the lung cancer risk associated with patients uses of ACEIs/ARBs.

Results: Thirty two studies met the inclusion criteria. In two investigations, individuals with advanced pancreatic cancer (HR=0.52, %CI 0.29-0.88) and non-small cell lung cancer (HR=0.56, %CI 0.33-0.95) had a substantial improvement in Overall Survival (OS).

Long-term usage of ACEIs/ARBs was linked to an elevated risk of lung cancer in six studies. While the other investigations concluded the use of ACEIs/ARBs was not significantly associated with increased risk of overall incident of lung cancer.

Conclusion: There is some evidence to suggest that ACEI or ARB use may be associated with lung cancer. Larger and more robust studies are required to explore this relationship further.